Zoetis Inc. (NYSE:ZTS) Position Lessened by Desjardins Global Asset Management Inc.

Desjardins Global Asset Management Inc. trimmed its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 9.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 82,703 shares of the company's stock after selling 8,774 shares during the period. Zoetis accounts for 1.7% of Desjardins Global Asset Management Inc.'s investment portfolio, making the stock its 9th biggest position. Desjardins Global Asset Management Inc.'s holdings in Zoetis were worth $16,323,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Enterprise Financial Services Corp boosted its holdings in Zoetis by 2.3% in the 1st quarter. Enterprise Financial Services Corp now owns 2,446 shares of the company's stock valued at $407,000 after purchasing an additional 55 shares during the period. CreativeOne Wealth LLC raised its position in shares of Zoetis by 0.4% during the 2nd quarter. CreativeOne Wealth LLC now owns 12,833 shares of the company's stock valued at $2,210,000 after buying an additional 57 shares in the last quarter. MJP Associates Inc. ADV raised its position in shares of Zoetis by 4.8% during the 3rd quarter. MJP Associates Inc. ADV now owns 1,275 shares of the company's stock valued at $222,000 after buying an additional 58 shares in the last quarter. River Street Advisors LLC raised its position in shares of Zoetis by 3.4% during the 4th quarter. River Street Advisors LLC now owns 1,757 shares of the company's stock valued at $347,000 after buying an additional 58 shares in the last quarter. Finally, Perigon Wealth Management LLC raised its position in shares of Zoetis by 0.3% during the 4th quarter. Perigon Wealth Management LLC now owns 23,581 shares of the company's stock valued at $4,654,000 after buying an additional 59 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Stifel Nicolaus lowered their price objective on shares of Zoetis from $215.00 to $195.00 and set a "buy" rating on the stock in a research report on Tuesday, April 2nd. StockNews.com cut shares of Zoetis from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, February 20th. The Goldman Sachs Group raised their price objective on shares of Zoetis from $190.00 to $226.00 and gave the company a "buy" rating in a research report on Wednesday, January 17th. Piper Sandler reiterated an "overweight" rating and issued a $195.00 target price (down previously from $220.00) on shares of Zoetis in a research report on Tuesday. Finally, Jefferies Financial Group reiterated a "buy" rating and issued a $230.00 target price on shares of Zoetis in a research report on Tuesday, December 19th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $221.75.

Zoetis Trading Up 2.2 %

Zoetis stock traded up $3.25 during trading hours on Tuesday, reaching $153.02. The stock had a trading volume of 4,967,362 shares, compared to its average volume of 2,959,312. The stock has a market cap of $69.99 billion, a PE ratio of 30.18, a PEG ratio of 2.29 and a beta of 0.85. Zoetis Inc. has a 52 week low of $148.48 and a 52 week high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. The company has a fifty day simple moving average of $178.25 and a 200-day simple moving average of $180.59.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.32 by ($0.08). The firm had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. Zoetis's revenue was up 8.5% on a year-over-year basis. During the same period last year, the business earned $1.15 EPS. Analysts forecast that Zoetis Inc. will post 5.8 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be issued a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a yield of 1.13%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis's dividend payout ratio (DPR) is presently 33.93%.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of the firm's stock in a transaction on Monday, February 12th. The shares were sold at an average price of $197.74, for a total value of $71,779.62. Following the sale, the executive vice president now owns 20,417 shares of the company's stock, valued at approximately $4,037,257.58. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 2,209 shares of company stock valued at $408,453 in the last quarter. Insiders own 0.12% of the company's stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.